文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

体外细胞因子清除对脓毒性休克患者临床与免疫学效应的随机对照试验

Clinical and Immunologic Effects of Extracorporeal Cytokine Removal in Patients with Septic Shock: A Randomized Controlled Trial.
PubMed 文献 · Shock · 2026-02-04
一句话结论单中心随机对照试验显示,对白介素-6>500 pg/mL的脓毒性休克患者早期启动CytoSorb血液吸附未改善升压药需求或临床结局,且对免疫反应无影响。

该单中心随机对照试验纳入31例成人脓毒性休克、已建立体外循环且白介素-6>500 pg/mL的患者,对照组接受指南标准治疗,干预组接受标准治疗联合CytoSorb血液吸附。主要终点72小时累积去甲肾上腺素剂量在对照组为78 mg(52.7-117.8 mg),干预组为100.7 mg(66.4-190.8 mg),差异未达统计学显著(P=0.09)。对照组48小时和72小时生存率均高于干预组,重症监护室死亡率、住院时间、休克持续时间及其他临床结局两组无差异。体液免疫反应两组相似,干预组前3天淋巴细胞百分比显著更低。结论认为早期启动体外血液吸附未改善升压药需求或临床结局,也未观察到对免疫反应的影响。

要点

  • 纳入标准为成人脓毒性休克、已建立体外循环且白介素-6>500 pg/mL,93%病例在脓毒性休克发病24小时内启动血液吸附。
  • 72小时累积去甲肾上腺素剂量对照组78 mg(52.7-117.8 mg)vs 干预组100.7 mg(66.4-190.8 mg),P=0.09,未达统计学显著。
  • 前72小时每小时存活期间总升压药剂量对照组1.2 mg(0.8-2.0 mg)vs 干预组2.5 mg(1.7-3.3 mg),P=0.0053,对照组显著更低。
  • 脓毒性休克发病后48小时生存率对照组100%(17/17)vs 干预组64%(9/14),P=0.01;72小时生存率对照组94%(16/17)vs 干预组57%(8/14),P=0.03,均为对照组更高。
  • 干预组前3天淋巴细胞百分比显著低于对照组(2.5%,2.1%-5.6% vs 6.2%,5.0%-17.4%,P=0.04),白细胞及淋巴细胞亚群和细胞毒能力未受血液吸附影响。

适用人群与场景

  • 成人脓毒性休克患者,已建立体外循环,且白介素-6>500 pg/mL。
  • 单中心随机对照试验场景,93%病例在脓毒性休克发病24小时内启动血液吸附。

诊断标准与关键阈值

  • 纳入标准:成人脓毒性休克、已建立体外循环、白介素-6>500 pg/mL。

处置流程与药物剂量

  • 对照组接受根据脓毒症指南的标准治疗。
  • 干预组接受标准治疗联合CytoSorb血液吸附,93%病例在脓毒性休克发病24小时内启动。

研究设计与关键结果

  • 单中心随机对照试验,纳入31例成人脓毒性休克伴高炎症反应患者(对照组17例,干预组14例),筛选58例。
  • 主要终点72小时累积去甲肾上腺素剂量:对照组78 mg(52.7-117.8 mg)vs 干预组100.7 mg(66.4-190.8 mg),P=0.09,未达统计学显著。
  • 前72小时每小时存活期间总升压药剂量:对照组1.2 mg(0.8-2.0 mg)vs 干预组2.5 mg(1.7-3.3 mg),P=0.0053,对照组显著更低。
  • 脓毒性休克发病后48小时生存率:对照组100%(17/17)vs 干预组64%(9/14),P=0.01,对照组更高。
  • 脓毒性休克发病后72小时生存率:对照组94%(16/17)vs 干预组57%(8/14),P=0.03,对照组更高。
  • 重症监护室死亡率、住院时间、脓毒性休克持续时间及其他临床结局两组无差异。
  • 体液免疫反应包括促炎和抗炎细胞因子两组相似;干预组前3天淋巴细胞百分比显著低于对照组(2.5%,2.1%-5.6% vs 6.2%,5.0%-17.4%,P=0.04),白细胞及淋巴细胞亚群和细胞毒能力未受血液吸附影响。

证据类型、等级与局限

  • 证据类型:单中心随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,对脓毒性休克患者早期启动体外血液吸附未改善升压药需求或临床结局,也未观察到对免疫反应的影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Immune dysregulation and excessive cytokine release characterize the early phase of septic shock. Extracorporeal hemoadsorption with the CytoSorb device aims to restore immune balance by removing inflammatory mediators. Currently, clinical benefits remain uncertain.

METHODS: In a single-center randomized controlled trial, 31 adult patients with septic shock, extracorporeal circuit, and interleukin-6 >500 pg/mL were included. The control group received standard care according to sepsis guidelines. The intervention group received standard care plus CytoSorb hemoadsorption. The primary outcome was the cumulative norepinephrine dose over 72 hours. Secondary outcomes included clinical and immunological endpoints.

RESULTS: Between February 2022 and July 2023, 58 patients with septic shock and hyperinflammation were screened for study inclusion. Seventeen patients were randomized to the control group, and 14 patients received extracorporeal cytokine removal. Hemoadsorption started within 24 hours after the onset of septic shock in 93% of cases. The cumulative norepinephrine dose in 72 hours was 78 mg (52.7-117.8 mg) in the control group and 100.7 mg (66.4-190.8 mg) with extracorporeal cytokine removal ( P = 0.09). The total vasopressor dose per hour alive in the first 72 hours was significantly lower in the control group compared with extracorporeal hemoadsorption (1.2 mg, 0.8-2.0 mg vs . 2.5 mg, 1.7-3.3 mg; P = 0.0053). Survival at 48 hours (100%, n = 17/17 vs . 64 %, n = 9/14; P = 0.01) and 72 hours (94%, n = 16/17 vs . 57%, n = 8/14; P = 0.03) after onset of septic shock was higher in the control group. Intensive care unit mortality, length of stay, duration of septic shock, and other clinical outcomes did not differ between the groups. The humoral immune response, including pro- and anti-inflammatory cytokines, was similar between groups. Compared with controls, patients with extracorporeal cytokine removal had significantly lower lymphocyte percentages during the first 3 days of septic shock (6.2%, 5.0% - 17.4% vs. 2.5%, 2.1% - 5.6%; P = 0.04), whereas leukocyte and lymphocyte subsets as well as cytotoxic capacities were not altered by hemoadsorption.

CONCLUSIONS: Early initiation of extracorporeal hemoadsorption in patients with septic shock did not improve vasopressor requirements or clinical outcomes, and no effects on the immune response were observed.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Lotz C, Heckelmann J, Lendzian C, et al. Clinical and Immunologic Effects of Extracorporeal Cytokine Removal in Patients with Septic Shock: A Randomized Controlled Trial. Shock. 2026. PMID: 41670614. doi:10.1097/SHK.0000000000002802

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。